AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

11.36

+0.08 (0.71%)

At close: Sep 2, 2026, 4:00 PM EDT

11.29

-0.07 (-0.62%)

Pre-market: Sep 3, 2026, 4:00 AM EDT

AbCellera Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	120.07	128.51	156.33	133.32	386.54	476.14
Short-Term Investments	420.04	405.31	469.29	627.27	499.95	246.84
Cash & Short-Term Investments	540.1	533.83	625.61	760.59	886.49	722.98
Cash Growth	-2.35%	-14.67%	-17.75%	-14.20%	22.62%	21.69%
Accounts Receivable	18.6	58.29	33.62	30.59	38.59	160.58
Other Receivables	38.41	55.7	26.53	33.79	64.82	14.28
Receivables	95.43	153.4	92.13	64.38	103.41	174.86
Inventory	7.58	6.34	-	-	1.53	1.67
Prepaid Expenses	11.12	9.67	8.63	22.02	9.06	5.29
Restricted Cash	25	25	25	25	25	25
Total Current Assets	679.23	728.23	751.37	871.99	1,025	929.8
Property, Plant & Equipment	416.68	428	340.43	287.7	217.26	111.62
Long-Term Investments	91.63	94.88	114.8	65.94	34.42	32.31
Goodwill	47.81	47.81	47.81	47.81	47.81	47.81
Other Intangible Assets	36.53	38.38	42.11	120.43	131.5	148.39
Other Long-Term Assets	35.7	19.65	34.44	80.34	40.83	30.64
Total Assets	1,308	1,357	1,361	1,488	1,541	1,319

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	12.11	25.23	34.35	28.6	14.83	14.92
Accrued Expenses	6.08	10.76	8.38	7.71	25.8	26.54
Current Portion of Leases	5.67	5.82	4.62	6.16	5.58	3.65
Current Income Taxes Payable	-	-	-	-	-	35.68
Current Unearned Revenue	29.34	22.51	21.18	26.07	27.9	12.01
Other Current Liabilities	-	-	8.09	50.48	44.21	27.87
Total Current Liabilities	53.19	64.31	76.61	119.01	118.32	120.68
Long-Term Leases	129.95	137.4	60.74	71.22	76.68	36.41
Long-Term Unearned Revenue	218.7	174.45	149.89	104.11	60.32	60.76
Long-Term Deferred Tax Liabilities	-	9.12	10.05	30.61	33.18	37.37
Other Long-Term Liabilities	9.71	4.77	7.17	10.82	19.14	37.62
Total Liabilities	411.56	390.05	304.47	335.78	307.63	292.84

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	821.24	802.34	777.17	753.2	734.37	722.43
Additional Paid-In Capital	206	198.28	166.36	121.05	74.12	35.36
Retained Earnings	-128.07	-29.48	116.93	279.79	426.19	267.67
Comprehensive Income & Other	-3.15	-4.23	-4.38	-1.72	-1.39	0.28
Total Common Equity	896.02	966.9	1,056	1,152	1,233	1,026
Shareholders' Equity	896.02	966.9	1,056	1,152	1,233	1,026
Total Liabilities & Equity	1,308	1,357	1,361	1,488	1,541	1,319

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	135.62	143.22	65.36	77.38	82.26	40.07
Net Cash (Debt)	404.49	390.61	560.25	683.21	804.23	682.91
Net Cash Growth	-1.58%	-30.28%	-18.00%	-15.05%	17.76%	15.80%
Net Cash Per Share	1.34	1.31	1.90	2.36	2.55	2.15
Filing Date Shares Outstanding	306.61	303.16	297.99	292.78	287.69	283.92
Total Common Shares Outstanding	306.47	300.6	295.76	290.82	286.85	283.26
Working Capital	626.04	663.93	674.76	752.97	907.17	809.12
Book Value Per Share	2.92	3.22	3.57	3.96	4.30	3.62
Tangible Book Value	811.68	880.72	966.17	984.09	1,054	829.54
Tangible Book Value Per Share	2.65	2.93	3.27	3.38	3.67	2.93
Land	53.41	53.41	53.41	53.41	53.41	33.04
Buildings	195.07	193.16	175.81	43.95	11.36	1.21
Machinery	105.91	102.94	84.29	73.87	49.56	26.65
Leasehold Improvements	-	-	-	73.94	40.57	22.75

SEC Filings: 10-K · 10-Q